Cucchiari, DavidEgri, NataliaRodriguez Espinosa, DianaMontagud Marrahi, EnriqueCasals Urquiza, JoaquimRisco Zevallos, Jimena delBodro, MartaVentura Aguiar, PedroCofán Pujol, FedericoCacho, JuditMolina Andújar, AlíciaRovira Juárez, JordiBañón Maneus, ElisendaRamírez Bajo, María JoséPérez Olmos, AnnaGarcia Pascual, MartaPascal i Capdevila, MarionaVilella i Morató, AnnaTrilla García, AntoniPalou, EduardRevuelta, IgnacioJuan, ManelCampistol Plana, Josep M.Oppenheimer Salinas, FedericoMoreno, AsunciónMiró Meda, José M. (José María), 1956-Bayés, BeatriuDiekmann, Fritz2023-08-012023-08-012022-10-072373-8731https://hdl.handle.net/2445/201402In kidney transplant recipients, there is discordance between the development of cellular and humoral response after vaccination against SARS-CoV-2. We sought to determine the interplay between the 2 arms of adaptive immunity in a 3-dose course of mRNA-1273 100 μg vaccine. Methods: Humoral (IgG/IgM) and cellular (N- and S-ELISpot) responses were studied in 117 kidney and 12 kidney-pancreas transplant recipients at the following time points: before the first dose, 14 d after the second dose' and before and after the third dose, with a median of 203 and 232 d after the start of the vaccination cycle, respectively. Results: After the second dose, 26.7% of naive cases experienced seroconversion. Before the third dose and in the absence of COVID-19, this percentage increased to 61.9%. After the third dose, seroconversion occurred in 80.0% of patients. Naive patients who had at any time point a detectable positivity for S-ELISpot were 75.2% of the population, whereas patients who maintained S-ELISpot positivity throughout the study were 34.3%. S-ELISpot positivity at 42 d was associated with final seroconversion (odds ratio' 3.14; 95% confidence interval' 1.10-8.96; P = 0.032). Final IgG titer was significantly higher in patients with constant S-ELISpot positivity (P < 0.001). Conclusions: A substantial proportion of kidney transplant recipients developed late seroconversion after 2 doses. Cellular immunity was associated with the development of a stronger humoral response11 p.application/pdfengcc-by-nc-nd (c) Cucchiari, David et al., 2022https://creativecommons.org/licenses/by-nc-nd/4.0/Trasplantament renalSARS-CoV-2VacunesRNAImmunoglobulinesResposta immunitàriaKidney transplantationSARS-CoV-2VaccinesRNAImmunoglobulinsImmune responseinfo:eu-repo/semantics/article7292722023-08-01info:eu-repo/semantics/openAccess933134136245998